NCT00585169

Memantine Treatment Study of Pathological Gambling

A Phase II Open-Label Multi-Center Trial of Memantine (Namenda(TM)) Treatment of Pathological Gambling

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 29 (actual)
• Sponsor: Yale University · Academic / Other
• Sex: All
• Age: 21 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The goal of the proposed study is to evaluate the efficacy and safety of the drug memantine in individuals with pathological gambling (PG). Thirty subjects with DSM-IV PG will receive 10 weeks of open-label treatment with memantine. The hypothesis to be tested is that memantine will be effective and well tolerated in patients with PG. We hypothesize that memantine will reduce the severity of gambling symptoms and improve patients' overall functioning. This study will provide needed data on the treatment of a disabling disorder that currently lacks a clearly effective treatment.

Conditions

• Pathological Gambling

Interventions

Type	Name	Description
DRUG	Memantine Hydrochloride	10 mg/day for two weeks, dose increase to 20 mg at week 3, 30 mg at week 4 unless clinical improvement is achieved with a lower dose. Total treatment is 10 weeks.

Timeline

• Start date: 2007-12-01
• Primary completion: 2011-12-01
• Completion: 2011-12-01
• First posted: 2008-01-03
• Last updated: 2013-04-08
• Results posted: 2013-04-08

Locations

2 sites across 1 country: United States